

August 13, 2026 03:17 AM GMT

Alchip Technologies Ltd | Asia Pacific

2Q26 preview: 3nm Trainium3 ramping nicely, what's next?

We keep our Street-high price target of NT\$5,088 to reflect Alchip's strong position in AWS Trainium ASIC design service. Additional project wins at other CSPs would bring our Bull Case into play.

2Q26 results preview: In our [Asia AI Summit 2026 Feedback \(31 May 2026\)](#), the company indicated its 3nm shipments were expected to surge in June and July, with maximum shipments starting in August. Full-year 3nm revenue was guided at US \$1.5bn+. We anticipate 3Q revenue to see a >250% Q/Q increase, with margins declining Q/Q to 18% given the Trainium3 turnkey revenue ramp.

Key questions for management at the earnings call on August 14: 1) Any increase in 2027 and 2028 ASIC TAM and Alchip's market share, given strong Trainium demand?; 2) 2nm tape-out appears on track for late 2026, with production and shipments expected for 4Q27. Any schedule change or a revenue gap between Trainium3 and Trainium4?; 3) How will you address competition from Marvell, Qualcomm, GUC, and MediaTek within AI ASIC?; 4) What's the chance to win new projects from other CSPs like Google and Meta?

Trainium4 the major growth driver in the next two years: Alchip continues to design for emerging accounts in the US that are investing heavily in innovative 3- and 2-nanometer projects to solve AI infrastructure bottlenecks. We expect Alchip to gradually tape out designs in the chiplets in 4Q27 and 1Q28. Some CPO optical I/O dies will still be at the engineering stage, and Alchip, as the design service vendor for the compute die, will know the progress of CPO adoption for the Trainium series. Although we believe Trainium4 is still several months from broad availability, our supply chain checks indicate Alchip has had its capacity reserved (suggesting mass production in 4Q27). Against this backdrop, we believe the TAM for Trainium is growing. We now forecast Trainium4 to contribute revenue of US\$4bn to Alchip in 2028 (400k units at ASP > US\$10k) vs. [our previous forecast](#) of 500k units at ASP US\$8k.

China AI CPU opportunities: For the China market, at our [Asia AI Summit](#), the company indicated ADAS chip for Li Auto is shipping, and its next-gen iteration is scheduled to tape out in 3Q26. Also, given the strong China AI CPU demand (see [Integrated CPU+GPU Compute](#)), we think Alchip can generate >US\$100mn in annual revenue from major China Arm-based CPU customers, such as [HJ Micro](#). We believe these China CPUs can be done by TSMC's 5nm nodes. Of note, TSMC and its design service comply with US export control rules, if the China CPU die size is within 300mm square.

MORGAN STANLEY TAIWAN LIMITED+

Charlie Chan		
Equity Analyst		
Charlie.Chan@morganstanley.com		+886 2 2730-1725
Daniel Yen, CFA		
Equity Analyst		
Daniel.Yen@morganstanley.com		+886 2 2730-2863
Tiffany Yeh		
Equity Analyst		
Tiffany.Yeh@morganstanley.com		+886 2 7712-3032
Lucas Wang		
Research Associate		
Lucas.Wang@morganstanley.com		+886 2 2730-2875



Alchip Technologies Ltd (3661.TW, 3661 TT)

Greater China Technology Semiconductors | Taiwan

Stock Rating	Overweight
Industry View	Attractive
Price target	NT\$5,088.00
Up/downside to price target (%)	25
Shr price, close (Aug 12, 2026)	NT\$4,055.00
52-Week Range	NT\$5,640.00-2,480.00
Mkt cap, curr (mn)	NT\$329,036
Avg daily trading value (mn)	NT\$7,922

Fiscal Year Ending	12/25	12/26e	12/27e	12/28e
EPS (NT\$)**	67.68	162.51	181.22	218.27
Prior EPS (NT\$)**	-	151.58	180.46	218.13
EPS (NT\$)§	65.78	138.09	180.95	240.97
Revenue, net (NT\$ mn)	30,926	92,826	134,592	165,265
P/E	51.9	25.0	22.4	18.6

Unless otherwise noted, all metrics are based on Morgan Stanley ModelWare framework
** = Based on consensus methodology
§ = Consensus data is provided by Refinitiv Estimates
e = Morgan Stanley Research estimates

Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report.

+ = Analysts employed by non-U.S. affiliates are not registered with FINRA, may not be associated persons of the member and may not be subject to FINRA restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

AlphaSignals Earnings Preview

Focus KPI	Focus KPI Surprise	Likely impact to consensus EPS*
-----------	--------------------	---------------------------------

Alchip Technologies Ltd 3661.TW

2Q26 Margin and 2H26 Revenue Guidance — In-line ↑ Modest revision higher

- 2Q26 preliminary revenue rose 82% Q/Q on the Trainium3 production ramp, and management will release the full 2Q26 result on Friday.
- Margins are expected to fall as turnkey mix rises, with 2Q around 30% and 3Q margin seen down to 18% alongside a >250% Q/Q revenue jump.

*Likely impact to consensus EPS is for the next 12 months
Source: Company data, Morgan Stanley Research

Alchip's near-term revenue momentum should accelerate in 3Q26 from Trainium3 ramp

Alchip's 2Q26 preliminary revenue was up 82% Q/Q given the Trainium3 production ramp. We expect 2Q26 and 3Q26 margin to decline significantly Q/Q due to higher turnkey revenue share. We therefore expect that 2Q margin was around 30%, similar to consensus. We anticipate 3Q revenue to see a significant increase of >250% Q/Q, with margin declining to 18% given the Trainium3 turnkey revenue ramp.

Exhibit 1: Alchip: 2Q26 earnings and 3Q26 guidance preview

(NT\$ mn)	2Q26					3Q26			
	Guidance	Prelim.	MSe	Consensus	Diff.	Guidance	Mse	Consensus	Diff.
Revenue	Revenue grow Q/Q	7,640	7,640	8,945	-15%		29,370	24,302	21%
Q/Q			82.5%	113.6%			284.4%	171.7%	
Y/Y			-16.4%	-2.2%			347.0%	269.9%	
GM (%)			30.0%	29.8%	0.2 ppt		18.0%	19.5%	-1.5 ppt
OpM (%)			19.6%	20.9%	-1.3 ppt		14.6%	15.1%	-0.5 ppt
Basic EPS (NT\$)			18.33	23.13	-21%		45.65	39.47	16%

Source: Company Data, Morgan Stanley research (e) estimates, Visible Alpha

After several collaboration announcements with AWS, we expect a bigger TAM for Trainium

According to an announcement, a major US AI company and Amazon have expanded collaboration for up to 5 gigawatts of new computing capacity for training and deployment, including new Trainium2 capacity coming online in 1H26 and nearly 1GW of combined Trainium2 and Trainium3 capacity by year-end 2026.

According to the announcement, the commitment spans Graviton and Trainium2 through Trainium4 chips, with an option to buy future generations of Amazon's custom silicon as they become available. On AWS's earnings call, management also said that Trainium3 started shipping at the start of 2026, offering 30-40% better price performance than Trainium2, and it is nearly fully subscribed. Although Trainium4 is still several months from broad availability, our channel checks suggest the capacity has already been reserved (suggesting mass production in 4Q27). Against this backdrop, we believe the TAM for Trainium is growing. We now forecast Trainium4 to contribute revenue of US\$4bn to Alchip in 2028 (400k units at ASP US\$10k) vs. [our previous forecast](#) of 500k units at ASP US\$8k.

Exhibit 2: AWS ASIC volume forecast from CoWoS and Morgan Stanley Asia's view

k Units	2023	2024	2025e	2026e	2027e	2028e
Trainium1/Inferentia2	300	600	30			
Trainium2		300	1,200			
Trainium3			85	1,700	2,380	-
Trainium4					150	2,000
Total	300	900	1,315	1,700	2,530	2,000

Source: Morgan Stanley Research (e) estimates; Company data

Alchip's 2026 revenue could improve >100% YoY

After a 40% Y/Y decline in 2025 NT\$ revenue, we expect Alchip's revenue to rebound strongly in 2026, mostly in 2H26, thanks to the Trainium3 and Li Auto contributions. We continue to expect Trainium3 volume at Alchip to be around 450k with ASP US\$4,400 in 2026. We believe other factors could include some Japanese consumer ASIC projects, as

well as low production of AI ASIC from US AI start-ups.

Exhibit 3: Our bottom-up assumptions for Alchip's revenue growth

Revenue (US\$ mn)	2025e	2026e	2027e	2028e	2025 Y/Y	2026 Y/Y	2027 Y/Y	2028 Y/Y
NRE								
Total NRE	321	403	350	373	-15%	26%	-13%	7%
Turnkey								
AWS	100	2,000	3,300	4,000	-86%	1900%	65%	21%
Intel Habana	300	0	0	0	50%	-100%	NA	NA
Amazon Lab126	40	50	50	50	-33%	25%	0%	0%
Sony	20	0	0	0	-60%	-100%	NA	NA
Chinese CPU	10	10	10	10	-75%	0%	0%	0%
Li Auto	20	350	500	700	NA	NA	NA	NA
Japan Consumer	30	80	100	100	NA	NA	NA	NA
Others	143	85	68	93	-25%	-41%	-20%	37%
Total turnkey	663	2,575	4,028	4,953	-47%	288%	56%	23%
Total revenue	984	2,978	4,378	5,326	-39%	203%	47%	22%

Revenue mix	2025e	2026e	2027e	2028e
NRE				
Total NRE	33%	14%	8%	7%
Turnkey				
AWS	10%	67%	75%	75%
Intel Habana	30%	0%	0%	0%
Amazon Lab126	4%	2%	1%	1%
Sony	2%	0%	0%	0%
Chinese CPU	1%	0%	0%	0%
Li Auto	2%	12%	11%	13%
Japan Consumer	3%	3%	2%	2%
Others	15%	3%	2%	2%
Total turnkey	67%	86%	92%	93%
Total revenue	100%	100%	100%	100%


Source: Company data, Morgan Stanley Research (e) estimates

The stock looks attractive on a long-term perspective

Alchip stock is trading at 22x our revised 2027e EPS, vs. its +1SD five-year average of 39x. Our price target implies a target multiple of 28x our 2027e EPS. We think the implied target multiple is justified because:

- We estimate a 2025-28 revenue CAGR of 75%;
- We continue to believe that AI ASICs will outgrow AI GPUs in the coming years; and
- Alchip is one of the few ASIC design service providers that can deal with increasingly complex designs (at 2nm) with good production/design track records for large leading-edge chips.

Exhibit 4: We expect AWS to account for c.65% of Alchip's 2026e revenue



Source: Company data, Morgan Stanley Research (e) estimates

Exhibit 5: Alchip: NTM rolling P/E



Source: Company data, FactSet, Morgan Stanley Research estimates

Alchip: Earnings estimates revision summary

We raise our earnings estimates 7% for 2026 and 0% for 2027/2028 estimates: Our 2026 revenue estimate increase 1% after we factor in 2Q26 preliminary revenue numbers, and our 2026e EPS increase 7% to reflect operating leverage and well-controlled opex. While our 2027/28 numbers remain largely unchanged.

Exhibit 6: Alchip: Earnings estimate revisions

NT\$ mn	New '26E	Old '26E	Diff.	New '27E	Old '27E	Diff.	New '28E	Old '28E	Diff.
Net sales	92,826	92,318	1%	134,592	134,592	0%	165,265	165,250	0%
Gross profit	18,973	18,559	2%	23,545	23,547	0%	28,549	28,546	0%
Operating profit	15,301	13,954	10%	17,423	17,462	0%	21,379	21,472	0%
Pretax Income	16,817	15,590	8%	18,755	18,677	0%	22,590	22,576	0%
Net income	13,455	12,550	7%	15,004	14,941	0%	18,072	18,061	0%
Reported EPS	162.51	151.58	7%	181.22	180.46	0%	218.27	218.13	0%
Margins									
Gross margin	20.4%	20.1%		17.5%	17.5%		17.3%	17.3%	
Operating margin	16.5%	15.1%		12.9%	13.0%		12.9%	13.0%	
Net margin	14.5%	13.6%		11.1%	11.1%		10.9%	10.9%	
Opex %	4.0%	5.0%		4.5%	4.5%		4.3%	4.3%	

Source: Morgan Stanley Research (E) estimates

Exhibit 7: Alchip: Quarterly financials

(NT\$ mn) YE DEC 31	1Q25	2Q25	3Q25	4Q25	1Q26	2Q26E	3Q26E	4Q26E	2023	2024	2025	2026E	2027E	2028E
Total revenues	10,485	9,144	6,570	4,727	4,187	7,640	29,370	51,629	30,482	51,969	30,926	92,826	134,592	165,265
Q/Q Change	-19.8%	-12.8%	-28.2%	-28.0%	-11.4%	82.5%	284.4%	75.8%						
Y/Y Change	0.0%	-32.7%	-55.7%	-63.8%	-60.1%	-16.4%	347.0%	992.1%	122.1%	70.5%	-40.5%	200.2%	45.0%	22.8%
Cost of Sales	8,056	7,257	4,729	2,730	2,086	5,348	24,084	42,336	23,687	41,768	22,772	73,854	111,047	136,715
Percent of Revenues	76.8%	79.4%	72.0%	57.7%	49.8%	70.0%	82.0%	82.0%	77.7%	80.4%	73.6%	79.6%	82.5%	82.7%
Gross Profit	2,429	1,887	1,841	1,997	2,101	2,292	5,287	9,293	6,794	10,201	8,154	18,973	23,545	28,549
Gross Margin	23.2%	20.6%	28.0%	42.3%	50.2%	30.0%	18.0%	18.0%	22.3%	19.6%	26.4%	20.4%	17.5%	17.3%
Incremental Margin	NM	NM	NM	NM	NM	6%	14%	18%	14%	16%	NM	17%	11%	16%
Total Opex	934	737	684	782	733	796	1,012	1,130	3,033	3,705	3,138	3,671	6,122	7,170
Percent of Revenues	8.9%	8.1%	10.4%	16.6%	17.5%	10.4%	3.4%	2.2%	10.0%	7.1%	10.1%	4.0%	4.5%	4.3%
R&D	467	494	453	417	508	558	608	608	1,547	2,142	1,831	2,281	3,545	3,938
Percent of Revenues	4.5%	5.4%	6.9%	8.8%	12.1%	7.3%	2.1%	1.2%	5.1%	4.1%	5.9%	2.5%	2.6%	2.4%
General & Adm Exp.	406	157	175	273	164	174	184	264	1,237	1,286	1,011	786	1,500	1,910
Percent of Revenues	3.9%	1.7%	2.7%	5.8%	3.9%	2.3%	0.6%	0.5%	4.1%	2.5%	3.3%	0.8%	1.1%	1.2%
Selling Expenses	61	86	56	92	61	64	221	258	250	276	295	604	1,077	1,322
Percent of Revenues	0.6%	0.9%	0.9%	2.0%	1.5%	0.8%	0.8%	0.5%	0.8%	0.5%	1.0%	0.7%	0.8%	0.8%
Operating Income	1,494	1,150	1,157	1,215	1,368	1,496	4,274	8,163	3,761	6,496	5,017	15,301	17,423	21,379
Operating Margin	14.3%	12.6%	17.6%	25.7%	32.7%	19.6%	14.6%	15.8%	12.3%	12.5%	16.2%	16.5%	12.9%	12.9%
Total Non-operating Income (loss)	299	449	433	522	416	366	366	366	436	1,312	1,703	1,515	1,332	1,211
Profit Before Taxes	1,793	1,599	1,591	1,737	1,784	1,862	4,641	8,530	4,198	7,808	6,720	16,817	18,755	22,590
Percent of Revenues	17.1%	17.5%	24.2%	36.7%	42.6%	24.4%	15.8%	16.5%	13.8%	15.0%	21.7%	18.1%	13.9%	13.7%
Taxes	332	277	265	250	357	373	928	1,706	877	1,362	1,124	3,364	3,751	4,518
Tax Rate	18.5%	17.3%	16.6%	14.4%	20.0%	20.0%	20.0%	20.0%	20.9%	17.4%	16.7%	20.0%	20.0%	20.0%
Minor interest	-2	-1	-2	3	-1	-1	-1	-1	-5	1	-2	-3	0	0
Total Net Income to Parent	1,464	1,324	1,328	1,483	1,428	1,491	3,713	6,824	3,325	6,446	5,598	13,455	15,004	18,072
Percent of Revenues	14.0%	14.5%	20.2%	31.4%	34.1%	19.5%	12.6%	13.2%	10.9%	12.4%	18.1%	14.5%	11.1%	10.9%
Y/Y change	19.0%	-16.6%	-25.9%	-19.2%	-2.4%	12.6%	179.6%	360.0%	81.3%	93.8%	-13.1%	140.3%	11.5%	20.4%
Diluted EPS (NT\$)	17.69	16.02	16.04	17.92	17.25	18.00	44.84	82.42	43.27	79.05	67.68	162.51	181.22	218.27
Reported Basic EPS (NT\$, TW GAAP)	18.13	16.37	16.40	18.33	17.55	18.33	45.65	83.89	45.42	81.51	69.22	165.42	184.46	222.18

Source: Company data, Morgan Stanley Research (E) estimates

Alchip: Valuation methodology

Price target unchanged at NT\$5,088: We continue to derive our base case value, which is also our price target, from a residual income model. All of our key assumptions are unchanged, including cost of equity of 10.4% (beta of 1.4, equity risk premium of 6.0%, and risk-free rate of 2.0%), intermediate growth rate of 16%, and terminal growth rate of 5.0%.

Our bear case value of NT\$2,130 and bull case value of NT\$5,950 also remain unchanged.

Exhibit 8: Alchip: Residual income model

NT\$ million	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E	2035E	2036E	2037E
Total Equity	40,824	50,448	56,199	67,135	79,820	94,536	111,605	131,406	154,374	181,018	211,925	247,776
Net Profit	13,455	15,004	18,072	20,964	24,318	28,209	32,722	37,958	44,031	51,076	59,248	68,728
ROAE	33.5%	32.9%	33.9%	34.0%	33.1%	32.4%	31.7%	31.2%	30.8%	30.5%	30.2%	29.9%
Residual Income	9,124	9,176	11,851	13,260	15,237	17,527	20,181	23,258	26,826	30,963	35,762	41,327
Spread	23.1%	22.5%	23.5%	23.6%	22.7%	22.0%	21.3%	20.8%	20.4%	20.1%	19.8%	19.5%
Ending Equity Capital	40,824											
PV of Forecast Period	109,777											
PV of Continuing Value	270,629											
Equity Value	421,230											
No. of Shares	83											
Projected Price	5,088											

Source: Morgan Stanley Research (E) estimates

Risk Reward – Alchip Technologies Ltd (3661.TW)


AI ASIC project demand remains strong in 2026-28

PRICE TARGET NT\$5,088.00


Base case value, derived from a residual income model. We assume the cost of equity is constant at 10.4% (2% risk-free rate, 6% risk premium, 1.4 beta). Our intermediate growth rate and terminal growth rates are 16% and 5%, respectively.

Consensus Price Target Distribution

Source: Refinitiv, Morgan Stanley Research



RISK REWARD CHART




Key: — Historical Stock Performance ● Current Stock Price ◆ Price Target

Source: Refinitiv, Morgan Stanley Research

OVERWEIGHT THESIS

- We continue to believe that AI ASICs will outgrow AI GPUs in the coming years, and Alchip is one of the few ASIC design service providers that can deal with increasingly complex designs (at 2nm) with good production/design track records for large leading edge chips.
- AWS's announcement of its 3nm Trainium3 chip matches the timing of Alchip's 3nm project win. The growing number of use cases for Trainium (e.g., Apple's adoption) bodes well for Alchip's revenue growth in 2026.
- We believe Alchip has strong potential to win Trainium4.
- Our price target implies 28x our 2027e EPS, which we find undemanding vs. our >70% revenue CAGR for 2025-28e.

Consensus Rating Distribution



Source: Refinitiv, Morgan Stanley Research

Risk Reward Themes

New Data Era: *Positive*

Secular Growth: *Positive*

View descriptions of Risk Rewards Themes [here](#)

BULL CASE

NT\$5,950.00

33x 2027e EPS

AI chipsets and HPC projects start to proliferate, amid substantial end demand. Alchip's leading-edge tape-out numbers increase significantly, with some high-profile project wins at 3nm or even 2nm. Alchip is able to secure enough foundry capacity (front-end wafers and back-end packaging) and substrates for all of its leading-edge turnkey production. Alchip gradually gains market share within the design service market, amid continued proliferation of custom chip demand.

BASE CASE

NT\$5,088.00

28x 2027e EPS

AI chipsets and HPC projects start to proliferate amid strong end demand, resulting in steady growth in tape-outs and volume. There might be a slowdown in Alchip's Chinese customers' design activity for leading-edge chips as a result of US export controls; we believe this would be largely offset by ASIC demand strength from non-China regions.

BEAR CASE

NT\$2,130.00

12x 2027e EPS

AI chipsets and HPC projects lack concrete end demand, resulting in delayed tape-outs and mass production. Alchip's leading-edge project pipeline deteriorates, or some customers turn directly to TSMC. AI GPU's dominance in AI computing compresses the market share gain potential for overall ASIC, with customers starting to slow their custom silicon developments - and therefore ASIC procurement plans.

Risk Reward – Alchip Technologies Ltd (3661.TW)


KEY EARNINGS INPUTS

Drivers	Dec 2025	Dec 2026e	Dec 2027e	Dec 2028e
HPC revenue (NT\$, mn)	25,816	62,194	90,177	110,727
Networking revenue (NT\$, mn)	698	6,498	9,421	11,569

INVESTMENT DRIVERS

- New promising AI chipset entrants
- NRE revenue growth
- Faster migration of semi industry to 7nm

GLOBAL REVENUE EXPOSURE



Source: Morgan Stanley Research Estimate
View explanation of regional hierarchies [here](#)

MS ALPHA MODELS

3/5
MOST

3 Month
Horizon

Source: Refinitiv, FactSet, Morgan Stanley Research; 1 is the highest favored Quintile and 5 is the least favored Quintile

RISKS TO PT/RATING

RISKS TO UPSIDE

- Demand for Chinese GPUs and AI chipsets takes off earlier than expected.
- NRE demand accelerates.
- Alchip wins more US hyperscaler HPC projects.

RISKS TO DOWNSIDE

- China's HPC localization progress slows down.
- AI chipset progress is much slower to develop.
- NRE demand decelerates.
- Pricing competition intensifies.

OWNERSHIP POSITIONING

Inst. Owners, % Active **62.7%**

Source: Refinitiv, Morgan Stanley Research

MS ESTIMATES VS. CONSENSUS

FY Dec 2026e

Sales / Revenue (NT\$, mn)

58,887 ◆ 74,187 ◆ 92,826

EBITDA (NT\$, mn)

10,163 ◆ 15,196 ◆ 18,045

Net income (NT\$, mn)

8,533 ◆ 11,239 ◆ 13,455

EPS (NT\$)

103.06 ◆ 138.09 ◆ 162.51

◆ Mean ◆ Morgan Stanley Estimates

Source: Refinitiv, Morgan Stanley Research

Alchip: Financial summary

Income Statement

NT\$m (Years End Dec)	2024	2025	2026E	2027E	2028E
Net sales	51,969	30,926	92,826	134,592	165,265
COGS	(41,768)	(22,772)	(73,854)	(111,047)	(136,715)
Gross profit	10,201	8,154	18,973	23,545	28,549
Operating expenses	(3,705)	(3,138)	(3,671)	(6,122)	(7,170)
Operating income	6,496	5,017	15,301	17,423	21,379
Non-operating income	1,312	1,703	1,515	1,332	1,211
Pre-tax income	7,808	6,720	16,817	18,755	22,590
Income tax	1,362	1,124	3,364	3,751	4,518
Minority Interest	1	(2)	(3)	0	0
Reported net Income	6,446	5,598	13,455	15,004	18,072
Adj.wtd.avg.shrs(m)	79	81	81	81	81
Reported EPS (NT\$)	79.05	67.68	162.51	181.22	218.27
Modelware EPS (NT\$)	79.05	67.68	162.51	181.22	218.27

Balance Sheet

NT\$m (Years End Dec)	2024	2025	2026E	2027E	2028E
Cash	27,044	32,627	17,979	8,197	4,970
Mkt Securities	16	163	163	163	163
AR/NR	5,730	3,011	13,118	19,020	23,354
Inventory	8,661	6,945	25,307	38,052	46,847
Other	4,733	10,311	10,311	10,311	10,311
Current Assets	46,184	53,057	66,877	75,742	85,645
Long-term investments	1,600	2,204	2,204	2,204	2,204
Fixed assets	1,775	1,680	1,680	1,680	1,680
Deferred assets	169	440	440	440	440
Other assets	582	659	659	659	659
Total Assets	50,309	58,039	71,859	80,724	90,627
S/T borrowings	0	0	0	0	0
AP/NP	1,826	1,986	6,183	9,297	11,446
Other ST liabilities	8,845	14,988	14,988	14,988	14,988
LT debt	0	0	0	0	0
Other LT liabilities	161	240	240	240	240
Common shares	806	813	813	813	813
Total Liabilities	10,833	17,214	21,411	24,525	26,674
Additional capital	25,350	25,755	25,755	25,755	25,755
Retained earning	10,752	13,405	23,029	28,780	36,534
Other shareholders' equity	2,568	852	852	852	852
Total Equity	39,477	40,824	50,448	56,199	63,953
Total Liab. & Shrhldr's Equity	50,309	58,039	71,859	80,724	90,627

E = Morgan Stanley Research Estimates

Source: Morgan Stanley Research, Company Data

Cash Flow Statement

NT\$m (Years End Dec)	2024	2025	2026E	2027E	2028E
Cashflow from Operations	3,358	15,272	(8,073)	2,215	9,835
Net profits	6,446	5,598	13,455	15,004	18,072
Depreciation	2,129	2,744	2,744	2,744	2,744
Working Capital Change	(869)	4,741	(24,272)	(15,533)	(10,981)
Other adjustments	(4,348)	2,189	0	0	0
Cashflow from Investing	(676)	(5,828)	(2,744)	(2,744)	(2,744)
Capex	(1,998)	(2,287)	(2,744)	(2,744)	(2,744)
Change of LT Investment	1,748	(3,701)	0	0	0
Change of ST Investment	(953)	(929)	0	0	0
Other adjustments	527	1,089	0	0	0
Cashflow from financing	12,855	(2,653)	(3,831)	(9,253)	(10,318)
Increase in L/T debt	0	0	0	0	0
Increase in S/T debt	0	0	0	0	0
Cash Dividend Paid	(1,818)	(2,946)	(3,831)	(9,253)	(10,318)
Issuance of stock	0	0	0	0	0
Other adjustments	14,673	293	0	0	0
Exchange rate adjustment	1,348	(1,208)	0	0	0
Net change in cash	16,885	5,583	-14,648	-9,782	-3,227

Financial Ratios

	2024	2025	2026E	2027E	2028E
Growth(%)					
Turnover	70.5	-40.5	200.2	45.0	22.8
Operating profits	72.7	-22.8	205.0	13.9	22.7
Pretax profits	86.0	-13.9	150.2	11.5	20.4
Net profits	93.8	-13.1	140.3	11.5	20.4
EPS	82.7	-14.4	140.1	11.5	20.4
Margins (%)					
Gross Margin	19.6	26.4	20.4	17.5	17.3
Operating Margin	12.5	16.2	16.5	12.9	12.9
Pretax Margin	15.0	21.7	18.1	13.9	13.7
Net Profit	12.4	18.1	14.5	11.1	10.9
Return (%)					
ROAE	22.4	13.9	29.5	28.1	30.1
ROAA	15.6	10.3	20.7	19.7	21.1
Gearing (%)					
Net Debt/Equity	(68.5)	(79.9)	(35.6)	(14.6)	(7.8)
Liabilities/Equity	27.4	42.2	42.4	43.6	41.7
Ratios (X)					
Current ratio	4.3	3.1	3.2	3.1	3.2
Quick ratio	3.1	2.1	1.5	1.1	1.1
Others					
AR/NR Turnover (days)	29	52	52	52	52
Inventory Turnover (days)	89	125	125	125	125
AP Turnover (days)	16	31	31	31	31
Cash Conversion (days)	101	146	146	146	146

Risk Reward Reference links

1. View explanation of Options Probabilities methodology - [Options_Probabilities_Exhibit_Link.pdf](#)
2. View descriptions of Risk Rewards Themes - [RR_Themes_Exhibit_Link.pdf](#)
3. View explanation of regional hierarchies - [GEG_Exhibit_Link.pdf](#)
4. View explanation of Theme/Exposure methodology - [ESG_Sustainable_Solutions_External_Link.pdf](#)
5. View explanation of HERS methodology - [ESG_HERS_External_Link.pdf](#)

Disclosure Section

The information and opinions in Morgan Stanley Research were prepared or are disseminated by Morgan Stanley Asia Limited (which accepts the responsibility for its contents) and/or Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research), and/or Morgan Stanley Taiwan Limited and/or Morgan Stanley & Co International plc, Seoul Branch, and/or Morgan Stanley Australia Limited (A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents), and/or Morgan Stanley Wealth Management Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents), and/or Morgan Stanley India Company Private Limited having Corporate Identification No (CIN) U22990MH1998PTC115305, regulated by the Securities and Exchange Board of India ("SEBI") and holder of licenses as a Research Analyst (SEBI Registration No. INH000001105); Stock Broker (SEBI Stock Broker Registration No. INZ000244438), Merchant Banker (SEBI Registration No. INM000011203), and depository participant with National Securities Depository Limited (SEBI Registration No. IN-DP-NSDL-567-2021) having registered office at Altimus, Level 39 & 40, Pandurang Budhkar Marg, Worli, Mumbai 400018, India; Telephone no. +91-22-61181000; Compliance Officer Details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: tejarshi.hardas@morganstanley.com; Grievance officer details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: msic-compliance@morganstanley.com which accepts the responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research, and their affiliates (collectively, "Morgan Stanley"). Morgan Stanley India Company Private Limited (MSICPL) may use AI tools in providing research services. All recommendations contained herein are made by the duly qualified research analysts.

For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/eqr/disclosures/webapp/generalresearch, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA.

For valuation methodology and risks associated with any recommendation, rating or price target referenced in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303-2495; Hong Kong +852 2848-5999; Latin America +1 718 754-5444 (U.S.); London +44 (0)20-7425-8169; Singapore +65 6834-6860; Sydney +61 (0)2-9770-1505; Tokyo +81 (0)3-6836-9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA.

Analyst Certification

The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report: Charlie Chan; Daisy Dai, CFA; Tiffany Yeh; Daniel Yen, CFA.

Global Research Conflict Management Policy

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflictolicies. A Portuguese version of the policy can be found at www.morganstanley.com.br

Important Regulatory Disclosures on Subject Companies

As of July 31, 2026, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: ACM Research Inc, Advanced Micro-Fabrication Equipment Inc, Advanced Wireless Semiconductor Co, **Alchip Technologies Ltd**, AllRng Tech Co., AP Memory Technology Corp, ASE Technology Holding Co. Ltd., ASMPT Ltd, Aspeed Technology, Cambricon Technology Corporation, GigaDevice Semiconductor Beijing Inc, GlobalWafers Co Ltd, Gudeng Precision, Hangzhou Silan Microelectronics Co. Ltd., Hua Hong Semiconductor Ltd, King Yuan Electronics Co Ltd, Macronix International Co Ltd, MediaTek, Montage Technology Co Ltd, NAURA Technology Group Co Ltd, Nuvoton Technology Corporation, Phison Electronics Corp, Powerchip Semiconductor Manufacturing Co, SG Micro Corp., Shanghai Fudan Microelectronics, Silergy Corp., Silicon Motion, StarPower Semiconductor Ltd, TSMC, UMC, Vanguard International Semiconductor, WIN Semiconductors Corp, Winbond Electronics Corp, WinWay Technology Co Ltd, WPG Holdings, WT Microelectronics Co. Ltd.. Within the last 12 months, Morgan Stanley managed or co-managed a public offering (or 144A offering) of securities of **Alchip Technologies Ltd**, Iluvatar CoreX Semiconductor Co., Ltd., Montage Technology Co Ltd, Powerchip Semiconductor Manufacturing Co.

Within the last 12 months, Morgan Stanley has received compensation for investment banking services from ASMPT Ltd, Iluvatar CoreX Semiconductor Co., Ltd., Montage Technology Co Ltd, Powerchip Semiconductor Manufacturing Co.

In the next 3 months, Morgan Stanley expects to receive or intends to seek compensation for investment banking services from Advanced Micro-Fabrication Equipment Inc, **Alchip Technologies Ltd**, AP Memory Technology Corp, ASE Technology Holding Co. Ltd., ASMedia Technology Inc, ASMPT Ltd, Aspeed Technology, Espressif Systems, GigaDevice Semiconductor Beijing Inc, GlobalWafers Co Ltd, Gudeng Precision, Himax Technologies Inc, Hua Hong Semiconductor Ltd, Iluvatar CoreX Semiconductor Co., Ltd., Innoscience, King Yuan Electronics Co Ltd, Macronix International Co Ltd, MediaTek, MetaX Integrated Circuits, Montage Technology Co Ltd, Novatek, Phison Electronics Corp, Powerchip Semiconductor Manufacturing Co, Realtek Semiconductor, SG Micro Corp., Shenzhen Longsys Electronics Co Ltd, SICC Co Ltd, Silergy Corp., Silicon Motion, TSMC, UMC, Universal Scientific Ind. (Shanghai), Vanguard International Semiconductor, Winbond Electronics Corp, WinWay Technology Co Ltd, WPG Holdings, WT Microelectronics Co. Ltd..

Within the last 12 months, Morgan Stanley has received compensation for products and services other than investment banking services from ASE Technology Holding Co. Ltd., King Yuan Electronics Co Ltd, MediaTek, Nanya Technology Corp., Novatek, Nuvoton Technology Corporation, Realtek Semiconductor, Silicon Motion, SMIC, TSMC, UMC, Universal Scientific Ind. (Shanghai), Winbond Electronics Corp, WT Microelectronics Co. Ltd..

Within the last 12 months, Morgan Stanley has provided or is providing investment banking services to, or has an investment banking client relationship with, the following company: Advanced Micro-Fabrication Equipment Inc, **Alchip Technologies Ltd**, AP Memory Technology Corp, ASE Technology Holding Co. Ltd., ASMedia Technology Inc, ASMPT Ltd, Aspeed Technology, Espressif Systems, GigaDevice Semiconductor Beijing Inc, GlobalWafers Co Ltd, Gudeng Precision, Himax Technologies Inc, Hua Hong Semiconductor Ltd, Iluvatar CoreX Semiconductor Co., Ltd., Innoscience, King Yuan Electronics Co Ltd, Macronix International Co Ltd, MediaTek, MetaX Integrated Circuits, Montage Technology Co Ltd, Novatek, Phison Electronics Corp, Powerchip Semiconductor Manufacturing Co, Realtek Semiconductor, SG Micro Corp., Shenzhen Longsys Electronics Co Ltd, SICC Co Ltd, Silergy Corp., Silicon Motion, TSMC, UMC, Universal Scientific Ind. (Shanghai), Vanguard International Semiconductor, Winbond Electronics Corp, WinWay Technology Co Ltd, WPG Holdings, WT Microelectronics Co. Ltd..

Within the last 12 months, Morgan Stanley has either provided or is providing non-investment banking, securities-related services to and/or in the past has entered into an agreement to provide services or has a client relationship with the following company: ASE Technology Holding Co. Ltd., Iluvatar CoreX Semiconductor Co., Ltd., King Yuan Electronics Co Ltd, MediaTek, Montage Technology Co Ltd, Nanya Technology Corp., Novatek, Nuvoton Technology Corporation, Realtek Semiconductor, Silicon Motion, SMIC, TSMC, UMC, Universal Scientific Ind. (Shanghai), Winbond Electronics Corp, WT Microelectronics Co. Ltd..

The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues. Equity Research analysts' or strategists' compensation is not

linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, providing liquidity, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report. Morgan Stanley trades or may trade as principal in the debt securities (or in related derivatives) that are the subject of the debt research report.

Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.

STOCK RATINGS

Morgan Stanley uses a relative rating system using terms such as Overweight, Equal-weight, Not-Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.

Global Stock Ratings Distribution

(as of July 31, 2026)

The Stock Ratings described below apply to Morgan Stanley's Fundamental Equity Research and do not apply to Debt Research produced by the Firm.

For disclosure purposes only (in accordance with FINRA requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal-weight, Not-Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal-weight and Not-Rated to hold and Underweight to sell recommendations, respectively.

Stock Rating Category	Coverage Universe		Investment Banking Clients (IBC)			Other Material Investment Services Clients (MISC)	
	Count	% of Total	Count	% of Total IBC	% of Rating Category	Count	% of Total Other MISC
Overweight/Buy	1529	42%	442	47%	29%	750	43%
Equal-weight/Hold	1582	43%	396	42%	25%	773	44%
Not-Rated/Hold	3	0%	1	0%	33%	1	0%
Underweight/Sell	560	15%	97	10%	17%	217	12%
Total	3,674		936			1741	

Data include common stock and ADRs currently assigned ratings. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months. Due to rounding off of decimals, the percentages provided in the "% of total" column may not add up to exactly 100 percent.

Analyst Stock Ratings

Overweight (O). The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Equal-weight (E). The stock's total return is expected to be in line with the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Not-Rated (NR). Currently the analyst does not have adequate conviction about the stock's total return relative to the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Underweight (U). The stock's total return is expected to be below the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.

Analyst Industry Views


Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below.

In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below.

Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant broad market benchmark, as indicated below.

Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.

Stock Price, Price Target and Rating History (See Rating Definitions)



Stock Rating History: 8/1/21 : 0/I; 10/12/21 : 0/C; 10/4/22 : 0/A; 2/22/23 : 0/I; 7/7/23 : 0/A; 7/21/24 : 0/I; 7/14/25 : 0/A

Price Target History: 4/12/21 : 780; 9/23/21 : 980; 10/8/21 : 1090; 10/30/21 : 1190; 2/10/22 : 1280; 3/7/22 : 1420; 10/18/22 : 1280; 3/13/23 : 1340; 4/26/23 : 1380; 5/10/23 : 1480; 6/12/23 : 1800; 7/3/23 : 2130; 7/7/23 : 2280; 8/14/23 : 2330; 9/12/23 : 2880; 11/3/23 : 3180; 1/2/24 : 3880; 2/14/24 : 4880; 6/10/24 : 4280; 9/26/24 : 3800; 12/16/24 : 3988; 7/3/25 : 4088; 8/12/25 : 4588; 9/17/25 : 4288; 11/5/25 : 4388; 5/7/26 : 5088

Source: Morgan Stanley Research Date Format : MM/DD/YY Price Target --- No Price Target Assigned (NA)

Stock Price (Not Covered by Current Analyst) — Stock Price (Covered by Current Analyst) —

Stock and Industry Ratings (abbreviations below) appear as ♦ Stock Rating/Industry View

Stock Ratings: Overweight (O) Equal-weight (E) Underweight (U) Not-Rated (NR) No Rating Available (NA)

Industry View: Attractive (A) In-line (I) Cautious (C) No Rating (NR)

Effective January 13, 2014, the stocks covered by Morgan Stanley Asia Pacific will be rated relative to the analyst's industry (or industry team's) coverage.

Effective January 13, 2014, the industry view benchmarks for Morgan Stanley Asia Pacific are as follows: relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.

Important Disclosures for Morgan Stanley Smith Barney LLC Customers

Important disclosures regarding any material conflict of interest that can reasonably be expected to have influenced Morgan Stanley Smith Barney LLC's choice of a third-party research provider or the subject company of a third-party research report, are available on the Morgan Stanley Wealth Management disclosure website at www.morganstanley.com/online/researchdisclosures. For Morgan Stanley specific disclosures, you may refer to <https://www.morganstanley.com/eqr/disclosures/webapp/generalresearch>.

Each Morgan Stanley research report is reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval is conducted by the same person who reviews the research report on behalf of Morgan Stanley. This could create a conflict of interest.

Other Important Disclosures

Morgan Stanley Research policy is to update research reports as and when the Research Analyst and Research Management deem appropriate, based on developments with the issuer, the sector, or the market that may have a material impact on the research views or opinions stated therein. In addition, certain Research publications are intended to be updated on a regular periodic basis (weekly/monthly/quarterly/annual) and will ordinarily be updated with that frequency, unless the Research Analyst and Research Management determine that a different publication schedule is appropriate based on current conditions.

Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

Morgan Stanley produces an equity research product called a "Tactical Idea." Views contained in a "Tactical Idea" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Matrix at <http://www.morganstanley.com/matrix>.

Morgan Stanley Research is provided to our clients through our proprietary research portal on Matrix and also distributed electronically by Morgan Stanley to clients. Certain, but not all, Morgan Stanley Research products are also made available to clients through third-party vendors or redistributed to clients through alternate electronic means as a convenience. For access to all available Morgan Stanley Research, please contact your sales representative or go to Matrix at <http://www.morganstanley.com/matrix>.

Any access and/or use of Morgan Stanley Research is subject to Morgan Stanley's Terms of Use (<http://www.morganstanley.com/terms.html>). By accessing and/or using Morgan Stanley Research, you are indicating that you have read and agree to be bound by our Terms of Use (<http://www.morganstanley.com/terms.html>). In addition you consent to Morgan Stanley processing your personal data and using cookies in accordance with our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html), including for the purposes of setting your preferences and to collect readership data so that we can deliver better and more personalized service and products to you. To find out more information about how Morgan Stanley processes personal data, how we use cookies and how to reject cookies see our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html). Please use the provided link to review the Terms and Conditions and Most Important Terms and Conditions for Morgan Stanley India Company Private Limited (https://www.morganstanley.com/assets/pdfs/about-us-global-offices/india/Terms_and_conditions.pdf) and the following link to review the audit report (https://ny.matrix.ms.com/eqr/research/webapp/researchdocs/MSICPL_Morgan_Stanley_Research_Audit_Report.pdf).

If you do not agree to our Terms of Use and/or if you do not wish to provide your consent to Morgan Stanley processing your personal data or using cookies please do not access our research.

Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the circumstances and objectives of those who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of an investment or strategy will depend on an investor's circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.

The fixed income research analysts, strategists or economists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

The "Important Regulatory Disclosures on Subject Companies" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities/instruments or derivatives of securities/instruments of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons.

With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre-approved by authorized members of Research management.

Morgan Stanley may make investment decisions that are inconsistent with the recommendations or views in this report.

To our readers based in Taiwan or trading in Taiwan securities/instruments: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited ("MSTL"). Such information is for your reference only. The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Any non-customer reader within the scope of Article 7-1 of the Taiwan Stock Exchange Recommendation Regulations accessing and/or receiving Morgan Stanley Research is not permitted to provide Morgan Stanley Research to any third party (including but not limited to related parties, affiliated companies and any other third parties) or engage in any activities regarding Morgan Stanley Research which may create or give the appearance of creating a conflict of interest. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments.

Certain information in Morgan Stanley Research was sourced by employees of the Shanghai Representative Office of Morgan Stanley Asia Limited for the use of Morgan Stanley Asia Limited. Morgan Stanley is not incorporated under PRC law and the research in relation to this report is conducted outside the PRC. Morgan Stanley Research does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves. Neither this report nor any part of it is intended as, or shall constitute, provision of any consultancy or advisory service of securities investment as defined under PRC law. Such information is provided for your reference only.

Morgan Stanley Research is disseminated in Brazil by Morgan Stanley C.T.V.M. S.A. located at Av. Brigadeiro Faria Lima, 3600, 6th floor, São Paulo - SP, Brazil; and is regulated by the Comissão de Valores Mobiliários; in Mexico by Morgan Stanley México, Casa de Bolsa, S.A. de C.V. which is regulated by Comisión Nacional Bancaria y de Valores. Paseo de los Tamarindos 90, Torre 1, Col. Bosques de las Lomas Floor 29, 05120 Mexico City; in Japan by Morgan Stanley MUFG Securities Co., Ltd. and, for Commodities related research reports only, Morgan Stanley Capital Group Japan Co., Ltd; in Hong Kong by Morgan Stanley Asia Limited (which accepts responsibility for its contents) and by Morgan Stanley Bank Asia Limited; in Singapore by Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research) and by Morgan Stanley Bank Asia Limited, Singapore Branch (Registration number T14FCO118); in Australia to "wholesale clients" within the meaning of the Australian Corporations Act by Morgan Stanley Australia Limited A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents; in Australia to "wholesale clients" and "retail clients" within the meaning of the Australian Corporations Act by Morgan Stanley Wealth Management Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents; in Korea by Morgan Stanley & Co International plc, Seoul Branch; in India by Morgan Stanley India Company Private Limited having Corporate Identification No (CIN) U22990MH1998PTC115305, regulated by the Securities and Exchange Board of India ("SEBI") and holder of licenses as a Research Analyst (SEBI Registration No. INH000001105); Stock Broker (SEBI Stock Broker Registration No. INZ000244438), Merchant Banker (SEBI Registration No. INM000011203), and depository participant with National Securities Depository Limited (SEBI Registration No. IN-DP-NSDL-567-2021) having registered office at Altimus, Level 39 & 40, Pandurang Budhkar Marg, Worli, Mumbai 400018, India; Telephone no. +91-22-61181000; Compliance Officer Details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: tejarshi.hardas@morganstanley.com; Grievance officer details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: msic-compliance@morganstanley.com. Morgan Stanley India Company Private Limited (MSICPL) may use AI tools in providing research services. All recommendations contained herein are made by the duly qualified research analysts; in Canada by Morgan Stanley Canada Limited; in Germany and the European Economic Area where required by Morgan Stanley Europe S.E., authorised and regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin) under the reference number 14-9169; in the US by Morgan Stanley & Co. LLC, which accepts responsibility for its contents. Morgan Stanley & Co. International plc, authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority, disseminates in the UK research that it has prepared, and research which has been prepared by any of its affiliates, only to persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"); (ii) are persons who are high net worth entities falling within Article 49(2)(a) to (d) of the Order; or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000, as amended) may otherwise lawfully be communicated or caused to be communicated. RMB Morgan Stanley Proprietary Limited is a member of the JSE Limited and A2X (Pty) Ltd. RMB Morgan Stanley Proprietary Limited is a joint venture owned equally by Morgan Stanley International Holdings Inc. and RMB Investment Advisory (Proprietary) Limited, which is wholly owned by FirstRand Limited. The information in Morgan Stanley Research is being disseminated by Morgan Stanley Saudi Arabia, regulated by the Capital

Market Authority in the Kingdom of Saudi Arabia, and is directed at Sophisticated investors only.

Morgan Stanley Hong Kong Securities Limited is the liquidity provider/market maker for securities of ASMP Ltd, GigaDevice Semiconductor Beijing Inc, Hua Hong Semiconductor Ltd, Montage Technology Co Ltd listed on the Stock Exchange of Hong Kong Limited. An updated list can be found on HKEx website: <http://www.hkex.com.hk>.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA) or by Morgan Stanley & Co. International plc (ADGM Branch), regulated by the Financial Services Regulatory Authority Abu Dhabi (the FSRA), and is directed at Professional Clients only, as defined by the DFSA or the FSRA, respectively. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria of a Professional Client. A distribution of the different MS Research ratings or recommendations, in percentage terms for Investments in each sector covered, is available upon request from your sales representative.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.

As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided exclusively to persons based on their risk and income preferences by the authorized firms. Comments and recommendations stated here are general in nature. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations.

The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages relating to such data. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and S&P.

Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

Indicators and trackers referenced in Morgan Stanley Research may not be used as, or treated as, a benchmark under Regulation EU 2016/1011, or any other similar framework.

The issuers and/or fixed income products recommended or discussed in certain fixed income research reports may not be continuously followed. Accordingly, investors should regard those fixed income research reports as providing stand-alone analysis and should not expect continuing analysis or additional reports relating to such issuers and/or individual fixed income products.

Morgan Stanley may hold, from time to time, material financial and commercial interests regarding the company subject to the Research report.

Registration granted by SEBI and certification from the National Institute of Securities Markets (NISM) in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

INDUSTRY COVERAGE: Greater China Technology Semiconductors

COMPANY (TICKER)	RATING (AS OF)	PRICE* (08/12/2026)
Charlie Chan		
ACM Research Inc (ACMR.O)	O (03/07/2023)	US\$81.26
Advanced Micro-Fabrication Equipment Inc (688012.SS)	O (11/06/2023)	Rmb380.95
Advanced Wireless Semiconductor Co (8086.TWO)	U (07/14/2025)	NT\$119.00
Alchip Technologies Ltd (3661.TW)	O (05/14/2021)	NT\$4,055.00
ASE Technology Holding Co. Ltd. (3711.TW)	O (09/15/2024)	NT\$621.00
Cambricon Technology Corporation (688256.SS)	O (04/27/2026)	Rmb1,105.38
Global Unichip Corp (3443.TW)	O (06/24/2026)	NT\$5,130.00
GlobalWafers Co Ltd (6488.TWO)	E (05/19/2026)	NT\$933.00
Gudeng Precision (3680.TWO)	O (11/25/2025)	NT\$452.50
Hua Hong Semiconductor Ltd (1347.HK)	E (03/12/2026)	HK\$142.80
Iluvatar CoreX Semiconductor Co., Ltd. (9903.HK)	O (04/27/2026)	HK\$416.60
King Yuan Electronics Co Ltd (2449.TW)	O (03/03/2023)	NT\$259.00
Maxscend Microelectronics Co Ltd (300782.SZ)	U (01/11/2021)	Rmb80.12
MediaTek (2454.TW)	O (11/28/2025)	NT\$4,015.00
MetaX Integrated Circuits (688802.SS)	E (04/27/2026)	Rmb715.29
Nanya Technology Corp. (2408.TW)	O (05/28/2026)	NT\$482.50
NAURA Technology Group Co Ltd (002371.SZ)	O (11/06/2023)	Rmb760.00
OmniVision Integrated Circuits Group Inc (603501.SS)	E (11/17/2025)	Rmb91.52
Phison Electronics Corp (8299.TWO)	E (02/25/2026)	NT\$2,210.00
SG Micro Corp. (300661.SZ)	E (11/03/2025)	Rmb116.02
Silergy Corp. (6415.TW)	U (05/19/2026)	NT\$449.00
SMIC (0981.HK)	O (10/21/2025)	HK\$67.40
TSMC (2330.TW)	O (02/07/2022)	NT\$2,415.00
UMC (2303.TW)	O (05/19/2026)	NT\$123.00
Vanguard International Semiconductor (5347.TWO)	E (01/14/2026)	NT\$159.50
WIN Semiconductors Corp (3105.TWO)	U (07/14/2025)	NT\$400.00

Daisy Dai, CFA

ASMP Ltd (0522.HK)	O (07/24/2025)	HK\$169.50
China Resources Microelectronics Limited (688396.SS)	U (03/02/2026)	Rmb62.02
Empyrean Technology Co Ltd (301269.SZ)	E (01/17/2025)	Rmb98.35
Hangzhou Silan Microelectronics Co. Ltd. (600460.SS)	U (08/25/2025)	Rmb32.85
Hygon Information Technology Co., Ltd. (688041.SS)	O (07/03/2026)	Rmb287.66
Innoscence (2577.HK)	E (10/13/2025)	HK\$44.78
JCET Group Co Ltd (600584.SS)	E (01/16/2026)	Rmb78.18
Shanghai Fudan Microelectronics (1385.HK)	O (03/07/2025)	HK\$26.98
SICC Co Ltd (688234.SS)	O (03/20/2026)	Rmb110.36
StarPower Semiconductor Ltd (603290.SS)	E (05/14/2026)	Rmb88.19
Unigroup Guoxin Microelectronics Co Ltd (002049.SZ)	U (01/10/2023)	Rmb67.28
Universal Scientific Ind. (Shanghai) (601231.SS)	O (11/05/2025)	Rmb28.13
Yangjie Technology (300373.SZ)	O (06/10/2022)	Rmb96.64

Daniel Yen, CFA

AP Memory Technology Corp (6531.TW)	O (07/11/2025)	NT\$878.00
ASMedia Technology Inc (5269.TW)	U (10/03/2025)	NT\$1,440.00
Aspeed Technology (5274.TWO)	O (06/09/2025)	NT\$17,370.00
Egis Technology Inc (6462.TWO)	E (01/28/2026)	NT\$101.50
Elan Microelectronics Corp (2458.TW)	O (10/03/2025)	NT\$146.00
Espressif Systems (688018.SS)	O (05/15/2023)	Rmb114.10
GigaDevice Semiconductor Beijing Inc (603986.SS)	O (05/15/2025)	Rmb413.17
Macronix International Co Ltd (2337.TW)	O (09/18/2025)	NT\$136.50
Montage Technology Co Ltd (6809.HK)	O (03/18/2026)	HK\$283.00
Montage Technology Co Ltd (688008.SS)	O (03/18/2026)	Rmb215.43
Novatek (3034.TW)	U (02/04/2026)	NT\$537.00
Nuvoton Technology Corporation (4919.TW)	U (11/10/2025)	NT\$125.50
Parade Technologies Ltd (4966.TWO)	O (05/27/2026)	NT\$591.00
Powerchip Semiconductor Manufacturing Co (6770.TW)	O (10/27/2025)	NT\$73.70
Realtek Semiconductor (2379.TW)	E (01/30/2026)	NT\$766.00
Shenzhen Goodix Technology Co Ltd (603160.SS)	U (07/14/2025)	Rmb52.20
Winbond Electronics Corp (2344.TW)	O (05/28/2026)	NT\$177.00
WPG Holdings (3702.TW)	O (03/16/2026)	NT\$122.50
WT Microelectronics Co. Ltd. (3036.TW)	O (01/27/2026)	NT\$217.50

Duan Liu

Dosilicon Co Ltd (688110.SS)	U (09/06/2024)	Rmb114.69
Shenzhen Longsys Electronics Co Ltd (301308.SZ)	E (02/25/2026)	Rmb414.30

Tiffany Yeh

AllRing Tech Co. (6187.TWO)	O (09/23/2025)	NT\$1,155.00
FOCI Fiber Optic Communications Inc (3363.TWO)	O (01/15/2025)	NT\$630.00
Himax Technologies Inc (HIMX.O)	E (02/04/2026)	US\$15.09
Hon Precision (7769.TW)	O (04/17/2026)	NT\$6,480.00
MPI Corporation (6223.TWO)	O (04/17/2026)	NT\$6,600.00
Silicon Motion (SIMO.O)	O (05/06/2024)	US\$241.31
WinWay Technology Co Ltd (6515.TW)	O (04/17/2026)	NT\$7,170.00

Stock Ratings are subject to change. Please see latest research for each company.

* Historical prices are not split adjusted.